Xembify
Payments companies reported to CMS as associated with Xembify. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.
By year
Payments reported as associated with Xembify, per program year, as reported to CMS.
Who makes it
Specialties most often involved
Where the associated payments went, by the receiving clinician's specialty.
Clinicians most associated with Xembify
These are the largest totals companies reported as associated with Xembify. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.
| Clinician | Location | Specialty | Associated payments (2023-2025) |
|---|---|---|---|
| Antoine Azar | Baltimore, MD | Allergy & Immunology (Internal Medicine) | $159,118.81 |
| Bob Geng | San Diego, CA | Allergy & Immunology | $135,227.66 |
| Manish Butte | Los Angeles, CA | Pediatric Allergy/Immunology | $116,072.39 |
| Raffi Tachdjian | Santa Monica, CA | Allergy & Immunology | $114,771.13 |
| Richard Wasserman | Dallas, TX | Allergy & Immunology | $104,760.92 |
| Russell Settipane | Middletown, RI | Allergy & Immunology | $73,686.79 |
| Lisa Satter | Houston, TX | Pediatric Allergy/Immunology | $65,797.17 |
| Marc Riedl | San Diego, CA | Allergy & Immunology | $45,862.98 |
| Michael Palumbo | Pittsburgh, PA | Allergy | $38,709.14 |
| Maeve Oconnor | Charlotte, NC | Allergy & Immunology | $32,709.10 |
Prescribed Xembify?
See what its makers reported for your doctor. Two steps, private, no account.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.